Wavena Raises Seed Funding for AI ECG Diagnostics

South Korean digital health innovator, Wavena, has successfully closed a seed funding round, securing approximately USD 150,000 from Seoul Techno Holdings. This capital infusion coincides with the company's selection for the Technology Innovation Program (TIPS), a government-backed initiative supporting advanced technology startups. The dual recognition underscores Wavena's potential to revolutionize diagnostic capabilities through its proprietary AI platform.

At the core of Wavena's technology is an artificial intelligence system capable of predicting over 30 blood biomarkers using only a 10-second electrocardiogram (ECG) reading. This groundbreaking approach bypasses the need for traditional blood draws, a process that can introduce significant delays in patient care. While conventional blood tests can take up to two hours from sample collection to result, Wavena's solution promises actionable insights within 30 minutes, dramatically accelerating the timeline for clinical decision-making and proactive interventions. This is particularly impactful in time-sensitive medical scenarios.

The company has built a substantial competitive advantage through its extensive dataset, comprising over 4 million meticulously matched ECG and blood sample records. This data was amassed from leading institutions including Seoul National University Hospital, Seoul National University Bundang Hospital, and Seoul National University Hospital Gangnam Healthcare Center. Leveraging this rich data foundation, Wavena has demonstrated exceptional performance, achieving AUROC scores between 0.89 and 0.92 for critical biomarkers such as hyperkalemia, renal function, anemia, and heart failure. This level of accuracy in non-invasive prediction is a significant leap forward in diagnostic technology.

The recent funding and TIPS program participation will fuel Wavena's research and development efforts, particularly in expanding its data acquisition network. The company plans to collaborate with 20 nephrology hospitals to gather further data and refine its algorithms, with a specific focus on improving diagnostics for hemodialysis patients. This strategic expansion aims to enhance the precision and applicability of its AI models across a wider patient demographic.

Wavena is actively pursuing commercialization across multiple fronts. Its pipeline includes Wavena Medical, a real-time alert system for dialysis centers targeting regulatory approval in South Korea early next year. Additionally, the company is developing Wavena One, a consumer-facing wellness application integrated with smartwatches, and GlucoWave, a non-invasive continuous glucose monitor. A further application, Wavet, is designed for companion animal ECG analysis, showcasing the versatility of their core technology.

Yongcheol Kim, CEO of Wavena and a practicing nephrologist at Seoul National University Hospital, expressed his honor at the validation of the company's innovation. He highlighted the transformative potential of needle-free diagnostics and the ambition to establish a new global standard for healthcare by harnessing the full capabilities of ECG data. Inhwan Cha, CEO of Seoul Techno Holdings, cited Wavena's advanced AI, clinical data foundation, and the founding team's medical expertise as key drivers for their investment, anticipating the TIPS program will further hone their technological edge for global market entry.